Parekh Kalpaj R, Adusumilli Prasad S, Patterson G Alexander
University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Natl Med J India. 2008 Sep-Oct;21(5):228-33.
The burden of chronic respiratory diseases in India is on the rise, accounting for nearly 1 in 10 deaths. Chronic obstructive pulmonary disease is highly prevalent in India and is projected to be the third leading cause of deaths worldwide by 2020. Improved access to healthcare and better imaging modalities have led to an increase in the diagnosis of pulmonary fibrosis and cystic fibrosis in India. For these end-stage lung diseases, lung transplantation is an effective and established treatment option in North America and Europe. The indications, techniques, outcomes and complications of lung transplantation are well documented. The criteria for recipient/donor selection are now better defined and the surgical technique has improved over the past 2 decades. Based on our experience of setting up a lung transplantation programme, we have outlined the resources required for the perioperative and postoperative management of such patients.
印度慢性呼吸道疾病的负担正在上升，几乎占十分之一的死亡病例。慢性阻塞性肺疾病在印度非常普遍，预计到2020年将成为全球第三大死亡原因。印度医疗保健服务的改善和更好的成像方式导致肺纤维化和囊性纤维化的诊断有所增加。对于这些终末期肺部疾病，肺移植在北美和欧洲是一种有效且成熟的治疗选择。肺移植的适应症、技术、结果和并发症都有充分的记录。受体/供体选择标准现在已得到更好的界定，并且在过去20年中手术技术也有所改进。基于我们建立肺移植项目的经验，我们概述了此类患者围手术期和术后管理所需的资源。
